Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

Benzinga Newsdesk www.benzinga.com Neutral 94.1%

Neg 0% Neu 94.1% Pos 0%

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026
HAELO manuscript simultaneously published in the New England Journal of Medicine

Comments

No comments yet. Be the first!